EUVIMEDEUVIMED entdecken
Crossref

Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Inhibitors: The Effect of Concurrent Medications on Patient Outcomes

Jussi Koivunen, Otto Manninen, Sanna Iivanainen, Martti Arffman, Jussi Pekka Koivunen

Oncology · 2025

DOI: 10.1159/000543163 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Jussi Koivunen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

EGFR-tyrosine kinase inhibitor (TKI)-induced rash can be alleviated with tetracyclines (TCN) and topical corticosteroids (TCS), whereas drugs for acid-related disorders (DARDs) can affect EGFR-TKI absorption. The present study investigated the concomitant use of TCNs, TCSs, and DARDs with EGFR-TKIs in non-small cell lung cancer (NSCLC) and whether these affect patient outcomes.

Methods

We retrospectively collected data from all patients (n = 1,498) who had purchased for EGFR-TKIs (erlotinib, gefitinib, and afatinib) in Finland between 2011 and 2020. Overall survival (OS) and time-on-treatment (ToT) were analyzed from the first EGFR-TKI purchase.

Results

Early TCN purchases were registered in 298 (19.6%) patients; early TCS and DARD purchases were observed in 154 (10.1%) and 192 (12.9%), while similar percentages were detected in the EGFR mutant cohort. In the entire cohort, early purchase of TCSs and TCNs was associated with improved ToT, OS, and DARDs with inferior outcomes. In the multivariate analysis, TCSs retained their significance in ToT (HR: 0.78; 95% CI: 0.66–0.94), TCNs in OS (HR: 0.73; 95% CI: 0.63–0.84), and DARDs in both (HR: 1.28; 95% CI: 1.091–1.495; HR: 1.19; 95% CI: 1.01–1.41). In the EGFR mutant cohort, similar nonsignificant trends were observed for TCNs, TCSs and DARDs. In the analysis according to EGFR-TKI, erlotinib users had improved outcomes when early TCN or TCS purchases were registered, whereas DARDs were associated with worse outcomes among gefitinib users.

Conclusions

Among EGFR-TKI-treated NSCLCs, the use of TCN, TCS, and DARD can affect treatment outcomes that should be considered in optimal patient care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsHumansMaleFemaleErbB ReceptorsRetrospective StudiesAgedMiddle AgedErlotinib HydrochlorideAfatinibGefitinibAged, 80 and overTreatment OutcomeAdultMutation

Stichwörter der Autor:innen

CorticosteroidDrug for acid-related disordersEGFR-tyrosine kinase inhibitorNon-small cell lung cancersProphylaxisTetracycline

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanErlotinib HydrochlorideAfatinibGefitinib

Autor:innen und Institutionen

  • Cancer Center and Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
  • Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.

Zitieren

APA

Koivunen, J., Manninen, O., Iivanainen, S., Arffman, M., & Koivunen, J. P. (2025). Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Inhibitors: The Effect of Concurrent Medications on Patient Outcomes. Oncology. https://doi.org/10.1159/000543163

Vancouver

Koivunen J, Manninen O, Iivanainen S, Arffman M, Koivunen JP. Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Inhibitors: The Effect of Concurrent Medications on Patient Outcomes. Oncology. 2025. doi:10.1159/000543163

BibTeX
@article{Koivunen2025,
  author = {Koivunen, Jussi and Manninen, Otto and Iivanainen, Sanna and Arffman, Martti and Koivunen, Jussi Pekka},
  title = {Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Inhibitors: The Effect of Concurrent Medications on Patient Outcomes},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000543163}
}
Kostenlos starten →